Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Recent Patents, Patent Applications Awarded to Isis, Alnylam, Alcon, and More


Title: Compositions and Methods for Topical Delivery of Oligonucleotides

Patent Number: 8,168,600

Filed: April 21, 2005

Lead Inventor: Sujatha Dokka, Isis Pharmaceuticals

The invention, the patent's abstract states, “relates to compositions and methods which enhance the delivery of nucleic acids and other nucleosidic moieties via topical routes of administration. The invention relates to the use of an aqueous solution to preferentially deliver nucleic acids preferentially to hair follicles. The invention relates to a method of inhibiting hair growth comprising administration of a nucleic acid preferentially to a hair follicle.”

Title: Method of Delivering RNA Interference and Uses Thereof

Patent Number: 8,168,601

Filed: Aug. 15, 2005

Lead Inventor: Judy Lieberman, Harvard University

The invention, the patent's abstract states, relates to a “method of RNA interference, which comprises contacting the cell with a fusion protein-double stranded RNA complex.”

The fusion protein comprises “a targeting moiety, which will specifically bind to a site on a target cell, and a binding moiety, which will bind to the double stranded RNA, wherein the double stranded RNA segment initiates RNA interference in the cell,” it adds.

Title: RNAi Inhibition of Alpha-ENaC Expression

Patent Number: 8,168,606

Filed: April 30, 2010

Lead Inventor: Gino Van Heeke, Novartis

“The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the down-regulation of alpha-ENaC expression by chemically modified oligonucleotides,” the patent's abstract states.

Title: Methods of Treating Eye Diseases in Diabetic Patients

Patent Number: 8,168,607

Filed: June 7, 2010

Lead Inventor: Elena Feinstein, Quark Pharmaceuticals (Silence Therapeutics)

The invention, the patent's abstract states, provides “novel molecules, compositions, methods, and uses for treating microvascular disorders, eye diseases, and respiratory conditions based upon inhibition of the RTP801 gene and/or protein.”

Title: RNAi-Mediated Inhibition of Rho Kinase for Treatment of Ocular Disorders

Patent Number: 8,168,609

Filed: Nov. 5, 2010

Lead Inventor: Jon Chatterton, Alcon

The patent, its abstract states, claims “RNA interference ... for [the] inhibition of Rho kinase mRNA expression for treating patients with ocular disorders, particularly for treating intraocular pressure, ocular hypertension, and glaucoma. Rho kinase mRNA targets include mRNA for ROCK1 and ROCK2.”

Title: Control of Gene Expression

Patent Number: 8,168,774

Filed: Sept. 2, 2005

Lead Inventor: Michael Graham, Commonwealth Scientific and Industrial Research Organization

The invention relates to “a method of modifying gene expression and to synthetic genes for modifying [endogenous] gene expression in a cell, tissue, or organ of a transgenic organism, in particular a transgenic animal or plant,” according to the patent's abstract. “More particularly, the invention utilizes recombinant DNA technology to post-transcriptionally modify or modulate the expression of a target gene in tissue, organ, or whole organism, thereby producing novel phenotypes. Novel synthetic genes and genetic constructs which are cap repressing delaying or otherwise reducing the expression of an endogenous gene or a target gene in an organism when introduced are also provided.”

Title: Compositions and Methods for Inhibiting Expression of Transthyretin

Patent Number: 8,168,775

Filed: Oct. 20, 2009

Lead Inventor: Dinah Sah, Alnylam Pharmaceuticals

“The invention relates to a double-stranded ribonucleic acid targeting a transthyretin gene, and methods of using the dsRNA to inhibit expression of TTR,” the patent's abstract states.

Title: Conjugates of Small Interfering Nucleic Acids

Application Number: 20120100096

Filed: Aug. 19, 2008

Lead Inventor: Samuel McManus, Nektar Therapeutics

The invention relates to “conjugates of small-interfering nucleic acids,” the patent application's abstract states. “Compositions of siNA suited for administration to a patient are described. Methods for delivering the compositions are also described.”

Title: Use of microRNAs to Control Virus Helper Nucleic Acids

Application Number: 20120100179

Filed: Nov. 25, 2009

Lead Inventor: Vernon Coffield, Alphavax

The invention, the patent application's abstract states, relates to “helper nucleic acids comprising at least one microRNA target sequence of an endogenous, cellular microRNA and a nucleic acid encoding a viral protein, wherein the microRNA target sequence is located in the untranslated or translated region of the nucleic acid encoding the viral protein. Also provided are vector systems, compositions and cells comprising the provided helper nucleic acids and a vector or replicon. Methods of making virus-like replicon particles and populations of virus-like replicon particles are also provided.”

Title: Transducible Delivery of Nucleic Acids Using Modified dsRNA Binding Domains

Application Number: 20120101045

Filed: May 7, 2010

Lead Inventor: Steven Dowdy, University of California, Oakland

The invention comprises “fusion polypeptides and constructs useful in delivering anionically charged nucleic acid molecules including diagnostics and therapeutics to a cell or subject,” according to the patent application's abstract. “The fusion constructs include a protein transduction domain and a nucleic acid binding domain, or a protein transduction domain and a nucleic acid that is coated with one or more nucleic acid binding domains sufficient to neutralize an anionic charge on the nucleic acid. Also provided are methods of treating disease and disorders such as cell proliferative disorders.”

Title: Lipid Formulation

Application Number: 20120101148

Filed: Jan. 29, 2010

Lead Inventor: Akin Akinc, Alnylam Pharmaceuticals

“The invention features an improved lipid formulation comprising a cationic lipid of [a predefined] formula, a neutral lipid, a sterol, and a PEG or PEG-modified lipid,” the patent application's abstract states. “Also disclosed are targeting lipids, and specific lipid formulations comprising such targeting lipids.”